Login to Your Account

Spinifex attracts $45M, and new backers on neuropathic pain data

By Nuala Moran
Staff Writer

Thursday, April 10, 2014
LONDON – Australian biotech Spinifex Pharmaceuticals carried the momentum generated by positive phase II data for its lead chronic pain program forward into a $45 million series C round that has attracted backing from premier U.S. and European investors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription